Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

Greenko, others looking to buy Equis#39; India hydropower assets: Report

2018-07-16 moneycontrol
Greenko Group and overseas vehicles utilities are in separate talks to acquire Equis Pte Ltd's Indian hydroelectric assets, according to a Mint report.

Greenko, others in talks for Equis’s India hydropower assets

2018-07-16 livemint
New Delhi: Greenko Group and overseas electric utilities are in separate talks with Equis Pte Ltd to acquire its Indian hydroelectric assets valued at around ₹2,700 crore, two people aware of the development said.

PE firms invest $8.2 bn in June quarter: Report

2018-06-29 thehindubusinessline
Private equity firms invested a record $8.2 billion across 158 deals during the quarter ended June, up 60 per cent over the year-ago period, largely driven by big ticket deals.

Steady cash flows, low risk make power transmission segment a safe bet

2018-06-24 livemint
Mumbai: With over 22,000 megawatts (MW) of installed power capacity starved of coal and natural gas supplies, power generation is no longer the hot investment target it used to be. What is taking its place—where everybody now wants a piece of the action—is last-mile delivery of power: transmission.

Day after Orange deal, Greenko Group gets $450 million from GIC, ADIA

2018-06-05 livemint
Hyderabad/New Delhi: Sovereign wealth funds GIC Holdings Pte Ltd and Abu Dhabi Investment Authority (ADIA) will invest a combined $450 million (around Rs3,000 crore) in Greenko Energy Holdings in one of the largest funding rounds by an Indian clean energy producer.

Greenko Group buys Orange Renewable at billion-dollar valuation

2018-06-03 livemint
Hyderabad/New Delhi: Greenko Group has agreed to buy Orange Renewable from Singapore’s AT Capital Group at an enterprise value of $1 billion, Greenko Group founder Mahesh Kolli said.

Greenko will add $10 billion in assets in 4-5 years: Anil Kumar Chalamalasetty

2018-06-03 livemint
Mumbai: Set up in 2006 by first-generation entrepreneurs Mahesh Kolli and Anil Kumar Chalamalasetty, Greenko Group is backed by Singapore’s sovereign wealth fund GIC Holdings Pte. Ltd and Abu Dhabi Investment Authority. Greenko president and joint managing director Kolli, and Chalamalasetty, the CEO and managing director, in an interview spoke about the rationale behind the acquisition of Orange Renewables, besides sharing their views on the sector.

Tata Power, Actis in fray to buy Essel’s solar power plants

2018-05-21 livemint
Tata Power Ltd and Actis LLP are in separate talks to buy the solar power business of Subhash Chandra’s Essel Infraprojects Ltd, two people aware of the development said.

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to LSE:GKO / GREENKO GROUP PLC on message board site Silicon Investor.

SCRO - HongKong/China PCB mfr..